<!--
Homepage version latest-updates

Instruction:

1. Always use three hashtags (###) to start a section title.

2. Please include an anchor link to the detailed latest updates page in each section title.
   You can click the üîó symbol on detailed latest updates page to find out the corresponding anchor link.
   Please follow the existing sections for the correct format.

3. One paragraph description for each section. The paragraph should contain less than ~200 chars.

4. Dated updates should be listed in descending order.

5. For links from covdb.stanford.edu, please remove the leading "https://covdb.stanford.edu".
   For example, "https://covdb.stanford.edu/page/updates/" should be shorten to "/page/updates/".

6. Try not to include plain links such as [https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).
   Please include readable content in the bracket, e.g. [video](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).

7. Please do not delete this instruction.

-->
### Database Entries (Jan 19)
Davies SP, Mycroft-West CJ, et int., and Richardson A. [‚ÄúThe hyperlipidaemic drug fenofibrate significantly reduces infection by SARS-CoV-2 in cell culture models.‚Äù](/search/?article=Davies21) _bioRxiv_, 2021. [doi.org/10.1101/2021.01.10.426114](https://doi.org/10.1101/2021.01.10.426114).
### Database Entries (Jan 19)
Kim C, Ryu D, et int., and Lee S. [‚ÄúA therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein.‚Äù](/search/?article=Kim21) _Nature Communications_, 2021. [doi.org/10.1038/s41467-020-20602-5](https://doi.org/10.1038/s41467-020-20602-5). \[[PubMed33436577](https://www.ncbi.nlm.nih.gov/pubmed/33436577/)\]
### Database Entries (Jan 19)
McCallum M, Marco AD, et int., and Veesler D. [‚ÄúN-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.‚Äù](/search/?article=McCallum21) _bioRxiv_, 2021. [doi.org/10.1101/2021.01.14.426475](https://doi.org/10.1101/2021.01.14.426475).
### Database Entries (Jan 19)
Tada T, Fan C, et int., and Landau NR. [‚ÄúAn ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2.‚Äù](/search/?article=Tada20) _Cell Reports_, 2020. [doi.org/10.1016/j.celrep.2020.108528](https://doi.org/10.1016/j.celrep.2020.108528). \[[PubMed33326798](https://www.ncbi.nlm.nih.gov/pubmed/33326798/)\] \[[PMC7705358](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705358/)\]
### Database Entries (Jan 15)
Biering SB, Van Dis E, et int., and Stanley SA. [‚ÄúScreening a library of FDA-approved and bioactive compounds for antiviral activity against SARS-CoV-2.‚Äù](/search/?article=Biering20) _bioRxiv_, 2020. [doi.org/10.1101/2020.12.30.424862](https://doi.org/10.1101/2020.12.30.424862).
### [Clinical Trials (Jan 14)](/page/updates/#clinical.trials)
[13 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2021-01-14)
### Database Entries (Jan 12)
Kirti R, Roy R, et int., and Sarfaraz A. [‚ÄúIvermectin as a potential treatment for mild to moderate COVID-19: A double blind randomized placebo-controlled trial.‚Äù](/search/?article=Kirti21) _medRxiv_, 2021. [doi.org/10.1101/2021.01.05.21249310](https://doi.org/10.1101/2021.01.05.21249310).

### [Clinical Trials (Jan 07)](/page/updates/#clinical.trials)
[11 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2021-01-07)

### Database Entries (Jan 05)
Sauer M, Park Y, et int., and Veesler D. [‚ÄúStructural basis for broad coronavirus neutralization.‚Äù](/search/?article=Veesler20) _bioRxiv_, 2020. [doi.org/10.1101/2020.12.29.424482](https://doi.org/10.1101/2020.12.29.424482).
### Database Entries (Jan 05)
Winkler ES, Gilchuk P, et int., and Diamond MS. [‚ÄúHuman neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection.‚Äù](/search/?article=Winkler20) _bioRxiv_, 2020. [doi.org/10.1101/2020.12.28.424554](https://doi.org/10.1101/2020.12.28.424554).
### [Clinical Trials (Dec 31)](/page/updates/#clinical.trials)
[2 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-12-31)
### Database Entries (Dec 30)
Ashhurst AS, Tang AH, et int., and Payne RJ. [‚ÄúPotent in vitro anti-SARS-CoV-2 activity by gallinamide A and analogues via inhibition of cathepsin L.‚Äù](/search/?article=Ashhurst20) _bioRxiv_, 2020. [doi.org/10.1101/2020.12.23.424111](https://doi.org/10.1101/2020.12.23.424111).
### Database Entries (Dec 28)
[‚ÄúA Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.‚Äù](/search/?article=ACTIV-3_LY-CoV55520) New England Journal of Medicine, 2020. [doi.org/10.1056/NEJMoa2033130](https://doi.org/10.1056/NEJMoa2033130).
### Database Entries (Dec 25)
Xie X, Muruato AE, et int., and Shi P. [‚ÄúA nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19.‚Äù](/search/?article=Xie20) _Nature Communications_, 2020. [doi.org/10.1038/s41467-020-19055-7](https://doi.org/10.1038/s41467-020-19055-7). \[[PubMed33060595](https://www.ncbi.nlm.nih.gov/pubmed/33060595/)\] \[[PMC7567097](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567097/)\]
### [Clinical Trials (Dec 24)](/page/updates/#clinical.trials)
[8 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2020-12-24)
